Rhythm Pharmaceuticals (RYTM) surges 35% after announcing Phase 2 trial data reveal for oral MC4R agonist bivamelagon

Why did Rhythm Pharmaceuticals stock surge more than 35% intraday on July 9, 2025?

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) witnessed a dramatic surge in trading activity on July 9, 2025, with its stock soaring 35.71% intraday to $88.40, a jump of $23.26 from the previous session. The spike came just hours before the American biopharmaceutical developer is set to unveil the topline results of its Phase 2 clinical trial for bivamelagon, an investigational oral melanocortin-4 receptor (MC4R) agonist. This trial targets a rare and debilitating condition known as acquired hypothalamic obesity, and the imminent data readout appears to have sparked significant institutional interest.

The surge follows the company’s July 8 press release, which confirmed it would release the data on July 9 at 8:00 a.m. ET via a conference call and webcast. Investor enthusiasm stems from anticipation that positive outcomes could potentially validate a new oral treatment pathway for patients suffering from neuroendocrine disorders with limited therapeutic options.

What are the key details of the Phase 2 trial for bivamelagon targeting hypothalamic obesity?

The Phase 2 trial conducted by Rhythm Pharmaceuticals evaluates the efficacy and safety of bivamelagon (also known as LB54640) in patients aged 12 and older diagnosed with acquired hypothalamic obesity. The randomized, placebo-controlled, double-blind study involves 28 participants who received either a low (200 mg), medium (400 mg), or high (600 mg) daily oral dose of bivamelagon—or placebo—over 14 weeks. The study’s primary endpoint is the change in body mass index (BMI) from baseline, and participants who complete the blinded phase are eligible to continue treatment under a 52-week open-label extension.

This trial is the first known late-stage clinical program targeting hypothalamic obesity with a melanocortin pathway agonist. With obesity research increasingly focusing on neurobiological and genetic drivers, Rhythm Pharmaceuticals’ work on MC4R agonists is attracting heightened attention from both researchers and investors. Institutional sentiment ahead of the readout reflects cautious optimism that bivamelagon could complement or potentially outperform its predecessor, setmelanotide, in select patient subpopulations.

How does bivamelagon fit into Rhythm Pharmaceuticals’ rare disease portfolio strategy?

Bivamelagon is part of Rhythm Pharmaceuticals’ broader pipeline strategy focused on rare neuroendocrine and genetic obesity disorders. The Boston-based commercial-stage biopharma is best known for IMCIVREE® (setmelanotide), another MC4R agonist already approved by the U.S. Food and Drug Administration (FDA) and regulators in Europe and the UK for treating monogenic and syndromic obesity caused by genetic mutations in the POMC, PCSK1, LEPR genes, and Bardet-Biedl Syndrome (BBS).

While setmelanotide is indicated for patients as young as 2 years of age, bivamelagon’s oral formulation is seen as potentially more accessible and easier to administer, expanding market applicability. If successful, it could unlock an addressable patient population underserved by current injectable treatments, especially those with acquired rather than inherited forms of hypothalamic dysfunction.

The strategic logic behind this portfolio is to own the rare obesity space through both inherited and acquired disease paths, and through both injectable and oral delivery mechanisms. Analysts suggest this dual-channel strategy may position Rhythm Pharmaceuticals as a dominant player in genetically driven metabolic disease treatment.

What are investors expecting from the upcoming topline results disclosure for bivamelagon?

With the topline results set to be announced at 8:00 a.m. ET on July 9, institutional investors are pricing in a potential clinical milestone that could significantly expand Rhythm Pharmaceuticals’ revenue potential. Speculation centers on whether the trial will demonstrate meaningful weight loss efficacy and improvements in hunger or quality of life metrics, as defined by its primary and secondary endpoints. If the trial meets or exceeds expectations, analysts believe Rhythm Pharmaceuticals may seek accelerated regulatory dialogue or even consider partnering opportunities.

Investor focus is also turning toward longer-term metrics—namely the magnitude of BMI reduction across dose cohorts, patient adherence trends over 14 weeks, and safety signals in this sensitive population. Given the company’s market capitalization climbing to approximately $5.6 billion intraday and a five-year monthly beta of 2.30, the volatility underscores how critical this readout could be in shaping Rhythm’s valuation narrative heading into Q3 2025 earnings.

How does today’s surge compare with Rhythm Pharmaceuticals’ historical stock performance?

The stock price of Rhythm Pharmaceuticals had closed the previous session at $65.14 and opened July 9 at $77.97, reflecting bullish pre-market sentiment. At its peak intraday, the stock touched $88.86—marking a new 52-week high and nearly doubling from its 52-week low of $40.61. Trading volume stood at over 3.6 million shares by 2:21 p.m. ET, substantially above the average daily volume of approximately 638,000 shares.

With no trailing twelve-month PE ratio currently posted, and an earnings per share (EPS) figure of -2.80, Rhythm Pharmaceuticals remains in a loss-making but potentially scalable stage of its commercial journey. While the 1-year analyst target stands at $83.42, the stock has already exceeded that figure intraday—underscoring heightened speculative activity in anticipation of clinical data.

What are the next catalysts and market implications for Rhythm Pharmaceuticals after the data reveal?

Beyond the topline data call, investors will be looking for regulatory signals and operational updates in Rhythm Pharmaceuticals’ Q2 earnings, scheduled for August 5, 2025. Should the results of the Phase 2 trial prove favorable, the American biopharmaceutical developer may move rapidly toward a Phase 3 pivotal trial or discuss exploratory pathways for Breakthrough Therapy designation.

The company’s future earnings visibility hinges on pipeline progress across its oral and injectable MC4R agonist platforms. Rhythm Pharmaceuticals is also developing RM-718, another MC4R agonist, and a portfolio of preclinical molecules targeting congenital hyperinsulinism, which collectively form its rare endocrine disease strategy. Analysts will be particularly attentive to management commentary regarding commercial expansion plans, payer coverage expectations, and additional trial readouts for 2025–2026.

Market sentiment remains volatile but generally optimistic as investors continue to rotate into biotech names with orphan drug potential and differentiated mechanisms. If bivamelagon data holds, Rhythm Pharmaceuticals could emerge as a key player in a niche but growing therapeutic category.